-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology

Benzinga·06/08/2026 06:43:34
Listen to the news
  • Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies
  • Collaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis)
  • Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors